Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Silo Pharma Inc
SILO
Healthcare
Biotechnology
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. The Company is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and...
researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. The Company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:SILO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
Next
(279)
•••
whytestocks
X
Post by
whytestocks
on Nov 29, 2024 10:15am
Silo Pharma Enters Joint Development Agreement for SP-26 Ket
NEWS: $SILO Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain ManagementPrototype development and feasibility testing underway for optimized subcutaneous
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Nov 18, 2024 7:00pm
Silo Pharma Announces Positive Results for Novel SPC-15 Trea
Just In: $SILO Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related DisordersDual-action approach combining 5-HT4R Agonist (SPC-15) and NMDAR antagonist
...more
(279)
•••
whytestocks
X
Post by
whytestocks
on Sep 10, 2024 5:15pm
Silo Pharma Announces Completion of FDA Pre-IND Meeting to A
News; $SILO Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSDProposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 14, 2024 2:30pm
New Press Release - Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgiaSever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatmentSARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Aug 07, 2024 8:13am
New Press Release - Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
Silo to advance homing peptide development for initial indication in multiple sclerosisSARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug...
read article.
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 03, 2024 6:46am
Silo Pharma, Inc. (NASDAQ:SILO) – A Promising Developm
https://beyondspx.com/2024/08/02/silo-pharma-inc-nasdaqsilo-a-promising-developmental-stage-biopharmaceutical-company/
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 26, 2024 8:20am
New Press Release - Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
Presentation to feature Silo’s novel therapeutics for the underservedSARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 22, 2024 4:45pm
New Press Release - Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced...
read article.
(279)
•••
whytestocks
X
Post by
whytestocks
on Jul 19, 2024 5:17pm
Silo Pharma Announces $2.1 Million Registered Direct Offerin
Just In: $SILO Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesSARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO
...more
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 19, 2024 8:18am
SILO...P.O announced
In hindsight......I sold too early....as usual all that volume was just a harbinger for this P.O announcement Always sell into the strength
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 19, 2024 8:01am
New Press Release - Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jul 18, 2024 8:25am
New Press Release - Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic BenefitThe Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental...
read article.
(279)
•••
whytestocks
X
Post by
whytestocks
on Jul 17, 2024 8:32pm
Using Volume Analysis to Trade Penny Stocks, 3 Tips
Breaking News: $SILO Using Volume Analysis to Trade Penny Stocks, 3 Tips2024-07-17 06:04:00 ET 3 Top Tips for Using Volume Analysis to Buy and Sell Penny Stocks Volume analysis is a crucial tool for
...more
(72)
•••
Iseneschal
X
Comment by
Iseneschal
on Jul 16, 2024 2:58pm
RE:Silo ....what a dump !!!!!!
Ooops .....I was on the 1 min chart.....LoL....not as bad as I referred to ....Lo Siento !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Jul 16, 2024 2:57pm
Silo ....what a dump !!!!!!
Got out just in time ....LoL
Prev
1
2
3
4
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments
Are PGM mining stocks an attractive area for your next portfolio allocation?
ReGen III Appoints New CEO and President to Accelerate Commercial and Strategic Opportunities